Does the media favor LBRX or AMRX?

In the previous week, Amneal Pharmaceuticals had 16 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 17 mentions for Amneal Pharmaceuticals and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Amneal Pharmaceuticals' score of 0.66 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, DFTX or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A

Is DFTX or LBRX more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% LB Pharmaceuticals N/A -25.92% -24.68%

Does the media prefer DFTX or LBRX?

In the previous week, Definium Therapeutics had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 6 mentions for Definium Therapeutics and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Definium Therapeutics' score of 0.37 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, LBRX or MANE?

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A Veradermics N/A N/A -$70M -$1.90 N/A

Is LBRX or MANE more profitable?

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Veradermics N/A N/A N/A

Does the media refer more to LBRX or MANE?

In the previous week, Veradermics had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Veradermics' score of 0.45 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INDV or LBRX?

In the previous week, Indivior had 7 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 8 mentions for Indivior and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Indivior's score of 0.55 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor OGN or LBRX?

In the previous week, Organon & Co. had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Organon & Co.'s score of 0.67 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

LB Pharmaceuticals (LBRX) Competitors

$39.19 -3.50 (-8.20%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$38.04 -1.15 (-2.93%)

As of 04:03 AM Eastern

Compare

LBRX vs. AMRX, DFTX, MANE, INDV, and OGN

Should you buy LB Pharmaceuticals stock or one of its competitors? LB Pharmaceuticals's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Organon & Co. (OGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Amneal Pharmaceuticals has a net margin of 5.05% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.92% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

LB Pharmaceuticals presently has a consensus price target of $49.63, suggesting a potential upside of 26.63%. Amneal Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 8.64%. Given LB Pharmaceuticals' higher probable upside, research analysts clearly believe LB Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

In the previous week, Amneal Pharmaceuticals had 16 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 17 mentions for Amneal Pharmaceuticals and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Amneal Pharmaceuticals' score of 0.66 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amneal Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Amneal Pharmaceuticals	$3.02B	2.04	$72.06M	$0.49	39.45

Summary

Amneal Pharmaceuticals beats LB Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Definium Therapeutics had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 6 mentions for Definium Therapeutics and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Definium Therapeutics' score of 0.37 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LB Pharmaceuticals' return on equity of -25.92% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Definium Therapeutics presently has a consensus target price of $64.88, indicating a potential upside of 72.31%. LB Pharmaceuticals has a consensus target price of $49.63, indicating a potential upside of 26.63%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Definium Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Summary

Definium Therapeutics beats LB Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Veradermics?

LB Pharmaceuticals (NASDAQ:LBRX) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

In the previous week, Veradermics had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Veradermics' score of 0.45 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals currently has a consensus price target of $49.63, indicating a potential upside of 26.63%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 32.20%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Veradermics	N/A	N/A	N/A

Summary

LB Pharmaceuticals and Veradermics tied by winning 5 of the 10 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Indivior?

Indivior (NASDAQ:INDV) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Indivior has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.42	$210M	$2.79	12.87
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Indivior has a net margin of 26.65% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Indivior currently has a consensus price target of $45.17, suggesting a potential upside of 25.78%. LB Pharmaceuticals has a consensus price target of $49.63, suggesting a potential upside of 26.63%. Given LB Pharmaceuticals' higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Indivior had 7 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 8 mentions for Indivior and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Indivior's score of 0.55 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Indivior beats LB Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Organon & Co. has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.84
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 17.00%. LB Pharmaceuticals has a consensus price target of $49.63, indicating a potential upside of 26.63%. Given LB Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe LB Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Organon & Co. had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Organon & Co.'s score of 0.67 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to LB Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Summary

Organon & Co. beats LB Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.38B	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-11.39	792.28	274.09	25.69
Price / Sales	N/A	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	3.29	10.58	10.47	6.32
Net Income	-$25.20M	$2.81B	$3.49B	$359.73M
7 Day Performance	-7.00%	-0.12%	-0.68%	0.17%
1 Month Performance	-18.71%	-1.34%	-3.18%	-3.27%
1 Year Performance	161.27%	2.86%	15.12%	5.58%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	2.6511 of 5 stars	$39.19 -8.2%	$49.63 +26.6%	+163.0%	$1.38B	N/A	N/A	27	Positive News
AMRX Amneal Pharmaceuticals	3.4801 of 5 stars	$17.22 +1.2%	$19.57 +13.7%	+96.4%	$5.43B	$3.02B	35.14	8,500	Analyst Forecast
DFTX Definium Therapeutics	2.8817 of 5 stars	$40.25 +3.5%	$63.33 +57.3%	+278.4%	$5.23B	N/A	N/A	40	High Trading Volume
MANE Veradermics	2.635 of 5 stars	$101.36 +2.4%	$153.00 +51.0%	N/A	$4.13B	N/A	N/A	21	Positive News
INDV Indivior	3.8545 of 5 stars	$34.47 -0.1%	$45.17 +31.0%	+54.9%	$4.07B	$1.24B	12.35	838	Positive News Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. AMRX, DFTX, MANE, INDV, and OGN

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Summary

How does LB Pharmaceuticals compare to Veradermics?

Summary

How does LB Pharmaceuticals compare to Indivior?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. AMRX, DFTX, MANE, INDV, and OGN

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

Is LBRX or AMRX more profitable?

Do analysts rate LBRX or AMRX?

Does the media favor LBRX or AMRX?

Do institutionals & insiders have more ownership in LBRX or AMRX?

Which has stronger earnings and valuation, LBRX or AMRX?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Does the media prefer DFTX or LBRX?

Is DFTX or LBRX more profitable?

Do analysts prefer DFTX or LBRX?

Do institutionals and insiders believe in DFTX or LBRX?

Which has higher earnings & valuation, DFTX or LBRX?

Summary

How does LB Pharmaceuticals compare to Veradermics?

Does the media refer more to LBRX or MANE?

Do analysts rate LBRX or MANE?

Which has better earnings and valuation, LBRX or MANE?

Is LBRX or MANE more profitable?

Summary

How does LB Pharmaceuticals compare to Indivior?

Which has higher valuation and earnings, INDV or LBRX?

Is INDV or LBRX more profitable?

Do analysts rate INDV or LBRX?

Do insiders & institutionals hold more shares of INDV or LBRX?

Does the media prefer INDV or LBRX?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Which has preferable earnings & valuation, OGN or LBRX?

Do analysts rate OGN or LBRX?

Does the media favor OGN or LBRX?

Do insiders & institutionals have more ownership in OGN or LBRX?

Is OGN or LBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools